Full name

A Phase II, Single-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of a Measles, Mumps, Rubella, Varicella Vaccine Compared With ProQuad, Administered in Healthy Children 4-6 Years of Age

NCT Number
NCT05630846
Geography
US
Non-US
Locations

Argentina, Chile, Colombia, Latvia, Puerto Rico, Spain, Taiwan, Turkey, United States

Primary Endpoints
  • Anti-measles antibody geometric mean concentrations (GMCs). At Day 43
  • Anti-mumps antibody GMCs. At Day 43
  • Anti-rubella antibody GMCs. At Day 43
  • Anti-glycoprotein E (gE) antibody GMCs. At Day 43
External Link
https://clinicaltrials.gov/study/NCT05630846
Order
0
Disease
Measles, Mumps, Rubella, Varicella
Menu title
A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age
Version
IDWEEK 2024
Phase
2